Breast Cancer Research and Treatment

, Volume 110, Issue 1, pp 169–176 | Cite as

ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study

  • Shimian Qu
  • Qiuyin Cai
  • Yu-Tang Gao
  • Wei Lu
  • Hui Cai
  • Yinghao Su
  • Shizhen Emily Wang
  • Xiao-Ou Shu
  • Wei Zheng


A polymorphism at codon 655 (ATC/isoleucine to GTC/valine [Ile655Val], rs1801200) in the transmembrane domain-coding region of human ERBB2 gene has been previously evaluated for its association with breast cancer risk with mixed results. We evaluated this polymorphism in association with breast cancer in a group of women who participated in a large-scale, population-based, case-control study of breast cancer in Shanghai, China, followed by an in vitro analysis of the function of this polymorphism. Genomic DNA from 3,012 patients with breast cancer and 3,004 healthy controls was examined for the Ile655Val polymorphism using a TaqMan genotyping method. Adjusted odds ratios (OR) were derived from multiple logistic regression. In vitro analyses were carried out to examine whether the Ile655Val polymorphism affect ERBB2 expression and the activity of its downstream targets. Approximately 2% of study subjects carry the Val/Val genotype. Compared with women with the Ile/Ile (76%) genotype, women who had the Ile/Val (22%) or Val/Val genotype did not have an elevated risk of breast cancer. Stratified analyses by age and menopausal status revealed no apparent association with this polymorphism in any subgroups of women. In a serious of biochemical analyses, we found that the Ile655Val substitution did not alter ErbB2 and its downstream signaling molecule activity. These study results suggest that Ile655Val polymorphism of the ERBB2 gene do not alter its activity and may not be associated with increased breast cancer risk among Chinese women.


ERBB2 Genetic polymorphism Breast cancer risk 



Confidence interval


Odds ratios


Body mass index


Epidermal growth factor receptor


Estrogen receptors


Mitogen-activated protein kinase


Phosphatidylinositol-3 kinase


Progesterone receptors


Shanghai Breast Cancer Study




  1. 1.
    Stern DF (2003) ErbBs in mammary development. Exp Cell Res 284:89–98PubMedCrossRefGoogle Scholar
  2. 2.
    Holbro T et al (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99–110PubMedCrossRefGoogle Scholar
  3. 3.
    Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137PubMedCrossRefGoogle Scholar
  4. 4.
    Pinkas-Kramarski R et al (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452–2467PubMedGoogle Scholar
  5. 5.
    Slamon DJ et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedCrossRefGoogle Scholar
  6. 6.
    Lemoine NR et al (1991) Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 64:79–83PubMedGoogle Scholar
  7. 7.
    Revillion F et al (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791–808PubMedCrossRefGoogle Scholar
  8. 8.
    Bargmann CI et al (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657PubMedCrossRefGoogle Scholar
  9. 9.
    Muller WJ et al (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115PubMedCrossRefGoogle Scholar
  10. 10.
    Guy CT et al (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578–10582PubMedCrossRefGoogle Scholar
  11. 11.
    Saya H et al (1990) Direct sequencing analysis of transmembrane region of human Neu gene by polymerase chain reaction. Mol Carcinog 3:198–201PubMedCrossRefGoogle Scholar
  12. 12.
    Lemoine NR et al (1990) Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5:237–239PubMedGoogle Scholar
  13. 13.
    Papewalis J et al (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19:5452PubMedCrossRefGoogle Scholar
  14. 14.
    Xie D et al (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412–417PubMedCrossRefGoogle Scholar
  15. 15.
    Baxter SW Campbell IG (2001) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:557–559CrossRefGoogle Scholar
  16. 16.
    Hishida A et al (2002) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94:1807–1808PubMedGoogle Scholar
  17. 17.
    Keshava C et al (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37–41PubMedCrossRefGoogle Scholar
  18. 18.
    Kean-Cowdin R et al (2001) Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61:8393–8394Google Scholar
  19. 19.
    Millikan R et al (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79:355–364PubMedCrossRefGoogle Scholar
  20. 20.
    Montgomery KG et al (2003) The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prev 12:1109–1111PubMedGoogle Scholar
  21. 21.
    Wang-Gohrke S, Chang-Claude J (2001) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:1657–1659PubMedCrossRefGoogle Scholar
  22. 22.
    Nelson SE et al (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:R357–R364PubMedCrossRefGoogle Scholar
  23. 23.
    Zubor P et al (2006) HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 53:49–55PubMedGoogle Scholar
  24. 24.
    Kamali-Sarvestani E et al (2004) Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215:83–87PubMedGoogle Scholar
  25. 25.
    Gao YT et al (2000) Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 87:295–300PubMedCrossRefGoogle Scholar
  26. 26.
    Wang SE et al (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25–38PubMedCrossRefGoogle Scholar
  27. 27.
    Colditz GA, Baer H, Tamimi RM (2006) Breast cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, pp 995–1012Google Scholar
  28. 28.
    Siegel PM et al (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068–7077PubMedGoogle Scholar
  29. 29.
    Bargmann CI et al (1988) Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. Embo J 7:2043–2052PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Shimian Qu
    • 1
  • Qiuyin Cai
    • 1
  • Yu-Tang Gao
    • 2
  • Wei Lu
    • 3
  • Hui Cai
    • 1
  • Yinghao Su
    • 1
  • Shizhen Emily Wang
    • 4
  • Xiao-Ou Shu
    • 1
  • Wei Zheng
    • 1
  1. 1.Department of Medicine, Vanderbilt Epidemiology Center, Institute of Medicine and Public HealthVanderbilt University School of MedicineNashvilleUSA
  2. 2.Department of EpidemiologyShanghai Cancer InstituteShanghaiChina
  3. 3.Shanghai Center for Disease Control and PreventionShanghaiChina
  4. 4.Department of Cancer BiologyVanderbilt University School of MedicineNashvilleUSA

Personalised recommendations